Base editing—the genome editing technique that alters base pairs using a nuclease-deficient Cas9 fused to a deaminase—was found to restart fetal hemoglobin expression in sickle cell disease (SCD) ...

Both CBEs and ABEs have been extensively engineered to improve their efficiency, specificity, and targeting range, enabling a wide variety of base pair conversions across the genome. Base editing can ...

Scientists at St. Jude Children’s Research Hospital and the Broad Institute of MIT and Harvard found base editing increased fetal hemoglobin production in a new treatment for sickle cell disease and ...

A new study describes a base editing method for treating spinal muscular atrophy (SMA). This supports early signs that “single-shot” treatments from clinical trials using genome editing technologies ...

Base editing has been lauded as a potential “game changer” for a broad swath of diseases, and Revvity is aiming to help usher in that change. After exclusively licensing a base editing system dubbed ...

Alyssa, 13, was the first patient to receive a base-edited cell therapy to treat her leukemia in May 2022.Great Ormond Street Hospital for Children A 13-year-old girl was the world's first patient to ...

Two new studies offer more validation that prime editing and base editing have the potential to permanently fix a gene variant associated with the rare disease phenylketonuria. In two separate papers ...

Beam is a leader in base editing and has strong lab data. It has a huge amount of cash and a major deal with Pfizer. Next year, Beam will produce first human data. I covered Beam Therapeutics (BEAM) ...

For the first time, a new gene editing technology called base editing was used to modify immune cells and successfully treat a teen with treatment-resistant leukemia. A month afterward, 13-year-old ...

A 13-year-old girl was the world's first patient to get a cell therapy called base editing in May. The experimental treatment has put her leukemia in remission for six months and counting. Base ...